{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:22Z","timestamp":1758121222187,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["apjon.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Oncology Nursing"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.apjon.2024.100495","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T06:07:36Z","timestamp":1713766056000},"page":"100495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nursing care for chimeric antigen receptor T cell therapy survivors: A\u00a0literature review"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-3112","authenticated-orcid":false,"given":"Mercedes","family":"Montoro-Lorite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Lahoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Bonilla-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Ayora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib1","first-page":"24","article-title":"Competencias de la enfermera de pr\u00e1ctica avanzada de hematolog\u00eda en la terapia CAR-T","volume":"23","author":"Montoro-Lorite","year":"2020","journal-title":"Metas Enfermer\u00eda"},{"year":"2022","series-title":"The EBMT\/EHA CAR-T Cell Handbook","key":"10.1016\/j.apjon.2024.100495_bib2"},{"issue":"2","key":"10.1016\/j.apjon.2024.100495_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","article-title":"The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001","volume":"57","author":"Trias","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.apjon.2024.100495_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1188\/21.CJON.255-258","article-title":"CAR T-cell therapy: updates in nursing management","volume":"25","author":"Baer","year":"2021","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.apjon.2024.100495_bib6","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Terapias Avanzadas. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/terapiasAvanzadas\/docs\/Plan_Abordaje_Terapias_Avanzadas_SNS_15112018.pdf Accessed 17 April 2024."},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","article-title":"The EBMT immune effector cell nursing guidelines on CAR-T therapy: a framework for patient care and managing common toxicities","volume":"4","author":"Ellard","year":"2022","journal-title":"Clin Hematol Int."},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"year":"2019","series-title":"Protocolo cl\u00ednico para el manejo de los efectos adversos graves en pacientes tratados con medicamentos que contienen c\u00e9lulas T CAR (chimeric antigen receptor) Anti-cd 19 (CART-19)","key":"10.1016\/j.apjon.2024.100495_bib9"},{"year":"2022","series-title":"Gu\u00eda de cuidados de enfermer\u00eda para pacientes que reciben terapia CAR-T","author":"Montoro-Lorite","key":"10.1016\/j.apjon.2024.100495_bib10"},{"issue":"suppl 4","key":"10.1016\/j.apjon.2024.100495_bib11","article-title":"How I treat adverse effects of CAR-T cell therapy","volume":"4","author":"Y\u00e1\u00f1ez","year":"2020","journal-title":"ESMO Open"},{"issue":"32","key":"10.1016\/j.apjon.2024.100495_bib12","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.apjon.2024.100495_bib13","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.apjon.2024.100495_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.apjon.2024.100495_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.apjon.2024.100495_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.apjon.2024.100495_bib17","first-page":"42","article-title":"Adult survivorship: considerations following CAR T-cell therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.apjon.2024.100495_bib18","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.apjon.2024.100495_bib20","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2021.01.003","article-title":"Patient-reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor T cell therapy: a systematic review","volume":"27","author":"Kamal","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"year":"2023","series-title":"Gu\u00eda para el manejo domiciliario y\/o ambulatorio de terapia celular con linfocitos CAR-T","author":"Mart\u00ednez-Roca","key":"10.1016\/j.apjon.2024.100495_bib22"},{"issue":"11","key":"10.1016\/j.apjon.2024.100495_bib23","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.apjon.2024.100495_bib24","doi-asserted-by":"crossref","first-page":"254.e1","DOI":"10.1016\/j.jtct.2023.01.004","article-title":"Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.apjon.2024.100495_bib26","unstructured":"Ackley BJ, Ladwig GB, Makic MBF, Martinez-Kratz MR, Zanotti M. Nursing Diagnosis Handbook, Revised Reprint with 2021-2023 NANDA-I\u00ae Updates-E-Book. Elsevier Health Sciences."},{"year":"2010","series-title":"Manual de valoraci\u00f3n de patrones funcionales","author":"Suarez","key":"10.1016\/j.apjon.2024.100495_bib27"},{"issue":"1","key":"10.1016\/j.apjon.2024.100495_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jan.14962","article-title":"Role of the nurse in the design, delivery, monitoring and coordination of cancer survivorship care plans: an integrative review","volume":"78","author":"Elizondo Rodriguez","year":"2022","journal-title":"J\u00a0Adv Nurs"},{"issue":"2","key":"10.1016\/j.apjon.2024.100495_bib29","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1634\/theoncologist.2019-0184","article-title":"Survivorship care plans in cancer: a meta-analysis and systematic review of care plan outcomes","volume":"25","author":"Hill","year":"2020","journal-title":"Oncol"},{"issue":"2","key":"10.1016\/j.apjon.2024.100495_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13187-018-1457-y","article-title":"Impact of survivorship care plans and planning on breast, colon, and prostate cancer survivors in a community oncology practice","volume":"35","author":"Hua","year":"2020","journal-title":"J\u00a0Cancer Educ"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/NCC.0000000000000704","article-title":"Primary care nursing is essential to fully implement survivorship care plans for long-term cancer survivors and their families","volume":"42","author":"Garcia-Vivar","year":"2019","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.apjon.2024.100495_bib32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.apjon.2024.100495_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"Eq-5D and the EuroQol group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Pol"},{"issue":"3","key":"10.1016\/j.apjon.2024.100495_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4045\/tidsskr.13.1145","article-title":"VAS--visuell analog skala [VAS--visual analog scale]","volume":"134","author":"Faiz","year":"2014","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"5","key":"10.1016\/j.apjon.2024.100495_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"year":"2023","series-title":"Nursing Interventions Classification (NIC)-E-Book: Nursing Interventions Classification (NIC)-E-Book","author":"Wagner","key":"10.1016\/j.apjon.2024.100495_bib36"},{"issue":"suppl 3","key":"10.1016\/j.apjon.2024.100495_bib37","first-page":"29","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre","year":"2019","journal-title":"J\u00a0Adv Pract Oncol"}],"container-title":["Asia-Pacific Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234756252400115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S234756252400115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:28:29Z","timestamp":1718681309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S234756252400115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S234756252400115X"],"URL":"https:\/\/doi.org\/10.1016\/j.apjon.2024.100495","relation":{},"ISSN":["2347-5625"],"issn-type":[{"type":"print","value":"2347-5625"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nursing care for chimeric antigen receptor T cell therapy survivors: A\u00a0literature review","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjon.2024.100495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Asian Oncology Nursing Society.","name":"copyright","label":"Copyright"}],"article-number":"100495"}}